Only the lung cancer effusion with the sensitive EGFR mutation, but not the EGFR wild-type one, responded to erlotinib in a dose-dependent manner, which confirms the relevance of this new in vitro test system. The gene discussed is EGFR; the disease is lung carcinoma.